logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Osteoporosis

    Medications for Osteoporosis

    FiltersReset Filters
    12 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • alendronate

      (Alendronate sodium tablet)
      Marlex Pharmaceuticals Inc
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, preventing postmenopausal osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in symptomatic patients or those at risk for complications. Reinforcement of therapy need is recommended periodically.

    • estradiol

      (Estradiol)
      Teva Pharmaceuticals USA, Inc.
      Usage: Estradiol tablets are indicated for treating moderate to severe menopause symptoms, vulvar and vaginal atrophy, hypoestrogenism, and for palliation in breast cancer and prostate cancer. They may also be used for preventing osteoporosis in postmenopausal women at significant risk when non-estrogen options are unsuitable.

    • forteo

      (Teriparatide)
      Eli Lilly and Company
      Usage: FORTEO is indicated for treating high-risk postmenopausal women and men with osteoporosis, including those intolerant to other therapies. It also increases bone mass in men with primary or hypogonadal osteoporosis and treats osteoporosis related to long-term glucocorticoid use, reducing fracture risk in these populations.

    • fosamax

      (alendronate sodium)
      Organon LLC
      Usage: FOSAMAX® is indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in men and women. Treatment duration and reevaluation of therapy needs are recommended periodically.

    • fosamax plus d

      (ALENDRONATE SODIUM and CHOLECALCIFEROL)
      Organon LLC
      Usage: FOSAMAX PLUS D is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It enhances bone mass and lowers the risk of fractures, but is not for treating vitamin D deficiency. Optimal duration and need for continued therapy must be periodically reassessed.

    • risedronate sodium

      (Risedronate Sodium)
      Greenstone LLC
      Usage: Risedronate Sodium is indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, and preventing glucocorticoid-induced osteoporosis. It also treats Paget’s disease of bone in both men and women. Optimal duration of therapy has not been established, warranting periodic re-evaluation.

    • risedronate sodium

      (Risedronate Sodium)
      Teva Pharmaceuticals USA, Inc.
      Usage: Risedronate sodium tablets are indicated for the treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget’s disease of bone. Regular evaluation of therapy necessity and fracture risk is recommended for long-term users.

    • risedronate sodium

      (Risedronate Sodium)
      Apotex Corp.
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. The safety and effectiveness are based on three years of clinical data. Regular re-evaluation of therapy needs is advised.

    • risedronate sodium

      (Risedronate Sodium)
      Aurobindo Pharma Limited
      Usage: Risedronate sodium is indicated for the treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease. It helps reduce the incidence of fractures and increases bone mass. Regular re-evaluation is recommended for ongoing treatment necessity.